Dapagliflozin suppresses glucagon signaling in rodent models of diabetes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 25, 2017, Pages 6611-6616

  Wang, May Yun ^a   Yu, Xinxin ^a   Lee, Young ^a   McCorkle, Sara Kay ^b   Chen, Shiuhwei ^a   Li, Jianping ^a,c   Wang, Zhao V ^a   Davidson, Jaime A ^a   Scherer, Philipp E ^a   Holland, William L ^a   Unger, Roger H ^a,b   Roth, Michael G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Dapagliflozin; Diabetes; Glucagon; Glucagon receptor; SGLT2 inhibition

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DAPAGLIFLOZIN; GLUCAGON; GLUCAGON RECEPTOR; GLUCOSE; GLYCOGEN; HEMOGLOBIN A1C; INSULIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PHOSPHOENOLPYRUVATE CARBOXYKINASE 2; PLACEBO; SMALL INTERFERING RNA; SODIUM GLUCOSE COTRANSPORTER 2; STREPTOZOCIN; UNCLASSIFIED DRUG; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DB/DB MOUSE; DRUG EFFECT; DRUG RESPONSE; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE URINE LEVEL; GLYCOGEN LIVER LEVEL; GLYCOGENOLYSIS; HEART FUNCTION; HEMOGLOBIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ZUCKER RAT; ANIMAL; DOWN REGULATION; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; KIDNEY PROXIMAL TUBULE; METABOLISM; PANCREAS ISLET ALPHA CELL; RAT; RODENT; SPRAGUE DAWLEY RAT;

ANIMALS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; GLUCAGON; GLUCAGON-SECRETING CELLS; GLUCOSE; GLUCOSIDES; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, PROXIMAL; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; RODENTIA; SIGNAL TRANSDUCTION; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85021095635     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1705845114     Document Type: Article

References (23)

1. Madaan T, Akhtar M, Najmi AK (2016) Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. Eur J Pharm Sci 93:244-252.
2. Tahrani AA, Barnett AH, Bailey CJ (2016) Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 12:566-592.
3. Hasan FM, Alsahli M, Gerich JE (2014) SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract 104:297-322.
4. Ferrannini E, et al. (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124:499-508.
5. Merovci A, et al. (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124:509-514.
6. Bonner C, et al. (2015) Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21:512-517.
7. Pedersen MG, Ahlstedt I, El Hachmane MF, Göpel SO (2016) Dapagliflozin stimulates glucagon secretion at high glucose: Experiments and mathematical simulations of human A-cells. Sci Rep 6:31214.
8. Wang MY, et al. (2015) Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci USA 112:2503-2508.
9. Olsen HL, et al. (2005) Glucose stimulates glucagon release in single rat alpha-cells by mechanisms that mirror the stimulus-secretion coupling in beta-cells. Endocrinology 146:4861-4870.
10. Unger RH, Cherrington AD (2012) Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 122:4-12.
11. Ramnanan CJ, Edgerton DS, Kraft G, Cherrington AD (2011) Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab 13:118-125.
12. Evans MR, Wei S, Posner BA, Unger RH, Roth MG (2016) An AlphaScreen assay for the discovery of synthetic chemical inhibitors of glucagon production. J Biomol Screen 21: 325-332.
13. Wu JS, et al. (2010) Discovery of non-glycoside sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors by ligand-based virtual screening. J Med Chem 53: 8770-8774.
14. Al-Awar A, et al. (2016) Experimental diabetes mellitus in different animal models. J Diabetes Res 2016:9051426.
15. Han S, et al. (2008) Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57:1723-1729.
16. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA (2016) SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG OUTCOME Study. Diabetes Care 39:717-725.
17. Scheen AJ (2016) Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. Diabetes Metab 42:71-76.
18. Scheen AJ (2016) Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Res Clin Pract 121:204-214.
19. Ali S, et al. (2014) Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. Mol Metab 4:132-143.
20. Zhou YT, et al. (2000) Lipotoxic heart disease in obese rats: Implications for human obesity. Proc Natl Acad Sci USA 97:1784-1789.
21. Ferrannini E, et al. (2016) Shift to fatty substrate utilization in response to sodiumglucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65:1190-1195.
22. Holland WL, et al. (2011) Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17:55-63.
23. Kusminski CM, et al. (2012) MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat Med 18:1539-1549.